QQQ   423.32 (-0.59%)
AAPL   166.76 (-0.74%)
MSFT   405.10 (-1.64%)
META   502.30 (+1.65%)
GOOGL   155.96 (+0.32%)
AMZN   178.91 (-1.31%)
TSLA   150.16 (-3.40%)
NVDA   844.72 (+0.52%)
AMD   154.32 (+0.19%)
NIO   4.01 (+2.56%)
BABA   68.90 (+0.12%)
T   16.23 (+0.68%)
F   12.00 (-0.33%)
MU   112.58 (-3.22%)
GE   153.59 (-1.34%)
CGC   8.15 (+25.58%)
DIS   112.80 (-0.12%)
AMC   2.91 (-2.35%)
PFE   25.31 (-0.43%)
PYPL   62.09 (-1.85%)
XOM   118.17 (-0.39%)
QQQ   423.32 (-0.59%)
AAPL   166.76 (-0.74%)
MSFT   405.10 (-1.64%)
META   502.30 (+1.65%)
GOOGL   155.96 (+0.32%)
AMZN   178.91 (-1.31%)
TSLA   150.16 (-3.40%)
NVDA   844.72 (+0.52%)
AMD   154.32 (+0.19%)
NIO   4.01 (+2.56%)
BABA   68.90 (+0.12%)
T   16.23 (+0.68%)
F   12.00 (-0.33%)
MU   112.58 (-3.22%)
GE   153.59 (-1.34%)
CGC   8.15 (+25.58%)
DIS   112.80 (-0.12%)
AMC   2.91 (-2.35%)
PFE   25.31 (-0.43%)
PYPL   62.09 (-1.85%)
XOM   118.17 (-0.39%)
QQQ   423.32 (-0.59%)
AAPL   166.76 (-0.74%)
MSFT   405.10 (-1.64%)
META   502.30 (+1.65%)
GOOGL   155.96 (+0.32%)
AMZN   178.91 (-1.31%)
TSLA   150.16 (-3.40%)
NVDA   844.72 (+0.52%)
AMD   154.32 (+0.19%)
NIO   4.01 (+2.56%)
BABA   68.90 (+0.12%)
T   16.23 (+0.68%)
F   12.00 (-0.33%)
MU   112.58 (-3.22%)
GE   153.59 (-1.34%)
CGC   8.15 (+25.58%)
DIS   112.80 (-0.12%)
AMC   2.91 (-2.35%)
PFE   25.31 (-0.43%)
PYPL   62.09 (-1.85%)
XOM   118.17 (-0.39%)
QQQ   423.32 (-0.59%)
AAPL   166.76 (-0.74%)
MSFT   405.10 (-1.64%)
META   502.30 (+1.65%)
GOOGL   155.96 (+0.32%)
AMZN   178.91 (-1.31%)
TSLA   150.16 (-3.40%)
NVDA   844.72 (+0.52%)
AMD   154.32 (+0.19%)
NIO   4.01 (+2.56%)
BABA   68.90 (+0.12%)
T   16.23 (+0.68%)
F   12.00 (-0.33%)
MU   112.58 (-3.22%)
GE   153.59 (-1.34%)
CGC   8.15 (+25.58%)
DIS   112.80 (-0.12%)
AMC   2.91 (-2.35%)
PFE   25.31 (-0.43%)
PYPL   62.09 (-1.85%)
XOM   118.17 (-0.39%)
Free Trial
NASDAQ:EIDX

Eidos Therapeutics (EIDX) Stock Price, News & Analysis

→ Nvidia Has a BIG Problem — Here’s Who Benefits MOST (From Weiss Ratings) (Ad)
Free EIDX Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$122.21
▼
$122.21
50-Day Range
$120.98
▼
$128.51
52-Week Range
$28.39
▼
$132.54
Volume
N/A
Average Volume
128,113 shs
Market Capitalization
$4.75 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
EIDX stock logo

About Eidos Therapeutics Stock (NASDAQ:EIDX)

Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.

EIDX Stock News Headlines

February 3, 2024 | thestreet.com
The Anglo File: Game Over for Board Lapses at Eidos
January 31, 2024 | msn.com
Deus Ex game canceled as nearly 100 Eidos-Montreal staff laid off
April 18, 2024 | GoldenCrest Metals (Ad)
Emergency: Biden's $20 Trillion Mistake Could Cost YOU!
The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.
January 31, 2024 | msn.com
Embracer Group reportedly cancels unannounced Deus Ex game, lays off staff at Eidos Montreal
January 31, 2024 | msn.com
Embracer lays off 97 Eidos employees and cancels new Deus Ex game
July 16, 2023 | investing.com
Eidos Therapeutics Inc (EIDX)
June 27, 2023 | finance.yahoo.com
VTGN - Vistagen Therapeutics, Inc.
April 7, 2023 | msn.com
Eidos' Guardians of the Galaxy Can Still Ride the Wave of Volume 3's May Release
April 18, 2024 | GoldenCrest Metals (Ad)
Emergency: Biden's $20 Trillion Mistake Could Cost YOU!
The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.
February 24, 2023 | benzinga.com
Cara Therapeutics Stock (NASDAQ:CARA), Quotes and News Summary
December 28, 2022 | finanznachrichten.de
Advanced Proteome Therapeutics Corp.: Advanced Proteome Therapeutics Announces Closing of Non-Brokered Private Placement
July 28, 2022 | msn.com
Sony Eyeing Square Enix Tokyo Purchase Months After Crystal Dynamics, Eidos Montreal Sale
July 26, 2022 | msn.com
Sony wants to buy Square Enix Tokyo claims Eidos-Montréal founder
May 2, 2022 | msn.com
The Eidos games that could be revived with the Embracer acquisition
May 2, 2022 | venturebeat.com
Embracer agrees to buy Crystal Dynamics, Eidos-Montréal, Square Enix Montréal, and their IP
October 8, 2021 | msn.com
Video-game studio Eidos-Montreal is switching to a 4-day work week for its staff, cutting weekly hours from 40 to 32 while keeping salaries the same
September 22, 2021 | news.yahoo.com
Eidos-Montréal gambles with entry into "Guardians of the Galaxy" franchise
July 24, 2021 | nasdaq.com
Eidos Therapeutics, Inc. Common Stock (EIDX)
See More Headlines
Receive EIDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eidos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/29/2020
Today
4/18/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:EIDX
CUSIP
N/A
CIK
N/A
Web
www.eidostx.com
Phone
415-887-1471
Fax
N/A
Employees
70
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.03)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-37,830,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-65.21%
Return on Assets
-53.04%

Debt

Debt-to-Equity Ratio
0.14
Current Ratio
11.10
Quick Ratio
11.10

Sales & Book Value

Annual Sales
$26.69 million
Price / Sales
177.99
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.57 per share
Price / Book
26.74

Miscellaneous

Outstanding Shares
38,873,000
Free Float
N/A
Market Cap
$4.75 billion
Optionable
Not Optionable
Beta
-0.16
The 10 Best AI Stocks to Own in 2024 Cover
The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Key Competitors

View All Competitors

EIDX Stock Analysis - Frequently Asked Questions

How were Eidos Therapeutics' earnings last quarter?

Eidos Therapeutics, Inc. (NASDAQ:EIDX) released its quarterly earnings data on Thursday, October, 29th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.71) by $0.08. The business had revenue of $0.13 million for the quarter.

What other stocks do shareholders of Eidos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eidos Therapeutics investors own include Exelixis (EXEL), CRISPR Therapeutics (CRSP), Aduro Biotech (ADRO), Micron Technology (MU), Pfizer (PFE), Verastem (VSTM), ImmunoGen (imgn), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY) and Axsome Therapeutics (AXSM).

When did Eidos Therapeutics IPO?

Eidos Therapeutics (EIDX) raised $101 million in an initial public offering (IPO) on Wednesday, June 20th 2018. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Barclays was co-manager.

This page (NASDAQ:EIDX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
Emergency: Biden's $20 Trillion Mistake Could Cost YOU!
GoldenCrest Metals
Next President (Not Trump. Not Biden.)
The Freeport Society
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
The only accurate crypto trading system I know …
Weiss Ratings